Interleukin-13 peptide kinoid vaccination attenuates allergic inflammation in a mouse model of asthma

• DOI: 10.3892/ijmm.2012.1036
• Publication Date: 2012-06-19T10:12:02Z
• Authors: QIUPING JING; TAO YIN; YANG WAN; HUASHAN SHI; SHUNTAO LUO; MENG LI; HAILONG ZHANG; HONG HE; SHIJIA LIU; HAOYU LI; YUQUAN WEI; LI YANG
• Keywords: Inflammation; 0301 basic medicine; Metaplasia; Mice, Inbred BALB C; Interleukin-13; Ovalbumin; Immunoglobulin E; Asthma; 3. Good health; Eosinophils; Disease Models, Animal; Mice; 03 medical and health sciences; Immunoglobulin G; Vaccines, Subunit; Animals; Cytokines; Female; Goblet Cells; Peptides; Bronchoalveolar Lavage Fluid

Asthma is an atopic disorder with increasing frequency and severity in developed nations. Interleukin-13 (IL-13) is one of the most critical mediators of asthma pathology. In the present study, we developed a vaccine comprised of a keyhole limpet hemocyanin-mIL-13 heterocomplex immunogen to persistently neutralize excessive endogenous IL-13. Our results showed that the IL-13 peptide kinoid vaccine could induce sustained and high titer of IL-13-specific IgG when using aluminum hydroxide as an adjuvant, and could suppress the accumulation of eosinophils as well as IL-13 levels in bronchoalveolar lavage fluid (BALF). In addition, total IgE and ovalbumin (OVA)-specific IgE in serum were significantly inhibited. This study also showed that vaccination could prevent airway inflammation and epithelial cell proliferation with goblet cell hyperplasia in a mouse model of acute asthma. In summary, our findings suggest that the IL-13 peptide kinoid can serve as an innovative and effective vaccine against asthma.